Programmed cell death ligand-1 （PD-L1） expression by immunohistochemistry： could it be predictive and/or prognostic in non-small cell lung cancer？-中国Betway体育网页登陆

摘要 Blockadeofimmunecheckpointshasrecentlyemergedasanoveltherapeuticstrategyinvarioustumors.Inparticular,monoclonalantibodiestargetingprogrammedcelldeath1(PD-1)oritsligand(PD-L1)havebeenmoststudiedinlungcancer,andPD-1inhibitorsarenowestablishedagentsinthemanagementofnon-smallcelllungcancer(NSCLC).ThereportsonhighprofileclinicaltrialshaveshowntheassociationofPD-L1expressionbyimmunohistochemistry(IHC)withhigheroverallresponseratestothePD-1/PD-L1axisblockadesuggestingthatPD-L1expressionmayserveasapredictivemarker.Unfortunately,however,eachPD-1orPD-L1inhibitoriscoupledwithaspecificPD-L1antibody,IHCprotocolandscoringsystemforthebiomarkerassessment,makingthehead-to-headcomparisonofthestudiesdifficult.Similarly,multipleclinicalseriesthatcorrelatedPD-L1expressionwithclinicopathologicand/ormolecularvariablesand/orsurvivalhavereportedconflictingresults.Thediscrepancycouldbeexplainedbythedifferencesinethnicityand/orhistologictypesincludedinthestudies,butitappearstobeattributedinparttothedifferencesinPD-L1IHCmethods.Thus,orchestratedeffortstostandardizethePD-L1IHCarewarrantedtoestablishtheIHCasapredictiveand/orprognosticbiomarkerinNSCLC.

1Cheng Ying,Li Hui,Zhang Liang,Liu Jing-Jing,Yang Chang-Liang,Zhang Shuang.Current and future drug combination strategies based on programmed death-1/programmed death-ligand 1 inhibitors in non-small cell lung cancer.医药卫生,2021-08.
2Zhao Jing,Huang Jian.Breast cancer immunology and immunotherapy: targeting the programmed cell death protein-1/programmed cell death protein ligand-1.医药卫生,2020-08.
3.Corrigendum: Breast cancer immunology and immunotherapy: targeting the programmed cell death protein-1/programmed cell death protein ligand-1.医药卫生,2021-03.
4Li Wen-Qian,Li Ling-Yu,Bai Ri-Lan,Qian Lei,Chen Nai-Fei,Cui Jiu-Wei.Cost-effectiveness of programmed cell death ligand 1 testing and tumor mutational burden testing of immune checkpoint inhibitors for advanced non-small cell lung cancer.医药卫生,2020-11.
5Yajing Zhang,Yangchun Feng,Xiaojie Sun.Recombinant human erythropoietin accelerated the proliferation of non-small cell lung cancer cell lines and reduced the expression of VEGF, HIF-1α, and PD-L1 under a simulated hypoxic environment in vitro.医药卫生,2022-12.
6Dylan A. Levy,Jaimin J. Patel,Shaun A. Nguyen,W. Nicholas Jungbauer,David M. Neskey,Ezra E. W. Cohen,Chrystal M. Paulos,John A. Kaczmar,Hannah M. Knochelmann,Terry A. Day.Programmed death 1 (PD-1) and ligand (PD-L1) inhibitors in head and neck squamous cell carcinoma: A meta-analysis.医药卫生,2022-12.
7Shu Zha;Minghui Zhang;Yu Zhang;Hongxue Meng;Yan Wang;Yupeng Liu;Jing Jing;Lan Huang;Mengqi Sun;Yue Zhang;Qingyuan Zhang.The prognostic value of programmed cell death ligand 1expression in non-Hodgkin lymphoma：a meta-analysis.肿瘤,2018-03.
8Zhou Fei,Zhou Cai-Cun.Immunotherapy in non-small cell lung cancer: advancements and challenges.医药卫生,2021-05.
9单根法;钟竑;张辅贤;李国庆;隆桂麟;顾鹤定;戚晓敏.Expression and Prognostic Significance of Multidrug Resistance Associated Protein (MRP) Gene in Non-small Cell Lung Cancer by in Site Hybridization.肿瘤,2000-03.
10林东;王恩华;张志坤;徐洪涛;李庆昌;邱雪杉.EXPRESSION OF PHOSPHO-b-CATENIN AND ITS SIGNIFICANCE IN NON-SMALL CELL LUNG CANCER.肿瘤,2003-01.

Programmed cell death ligand-1 （PD-L1） expression by immunohistochemistry： could it be predictive and/or prognostic in non-small cell lung cancer？

来源期刊

相关推荐

同分类资源更多

相关关键词